Drugs / Ad26.RSV.preF
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04354480 | May 2020 → Jan 2021 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT03795441 | Jan → Jul 2019 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1 | NCT02926430 | Nov 2016 → Mar 2018 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03606512 | Jan 2019 → Nov 2021 | respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT03502707 | Jul 2018 → May 2022 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT03303625 | Nov 2017 → Apr 2020 | respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04453202 | Jul → Sep 2020 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 2 | NCT03339713 | Dec 2017 → Jul 2018 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 2 | NCT03334695 | Oct 2017 → Jul 2018 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04908683 | Jul 2021 → Jul 2023 | lower respiratory tract disorder, respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.RSV.preF | “A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in...” NCT04908683 ↗9“A combination vaccine containing Ad26.RSV.preF and purified recombinant RSV preF protein has previously demonstrated efficacy and tolerability in older adults.” PMID 39276619 ↗ Sep 2024 “Hence, Ad26.RSV.preF/RSV preF protein vaccine candidate was evaluated in the Japanese older adult population.” PMID 38880785 ↗ Jun 2024 |
| Modality | Vaccine | “an investigational RSV vaccine candidate” NCT03303625 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT02926430 ↗ |